Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Download PDF
Semin Thromb Hemost 2007; 33(8): 787-797
DOI: 10.1055/s-2007-1000365
DOI: 10.1055/s-2007-1000365
Reduced von Willebrand Factor-Cleaving Protease Levels in Secondary Thrombotic Microangiopathies and Other Diseases
Further Information
Publication History
Publication Date:
04 January 2008 (online)
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a severe multisystem thrombotic microangiopathy (TMA). Significant advances have been made in understanding the pathogenesis of TTP since the discovery of ADAMTS-13 (a disintegrin and metalloproteinase with thrombospondin-1-like domains), the enzyme that regulates the size of von Willebrand factor (VWF) multimers. The inherited forms of TTP are mainly caused by a severe ADAMTS-13 deficiency, yet many aspects of the complex biological relationships between VWF-cleaving metalloproteinase and acquired TMA are still unclear. This latter issue will be critically addressed in this review article. In addition, the published literature evaluating plasma ADAMTS-13 levels in other pathologic conditions different from TMA will also be discussed.
KEYWORDS
ADAMTS-13 - von Willebrand factor - thrombotic microangiopathy
REFERENCES
- 1 Tsai H M. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006; 57 419-436
- 2 Franchini M, Zaffanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Thromb Res. 2006; 118 177-184
- 3 Moake J L. Thrombotic microangiopathies. N Engl J Med. 2002; 347 589-600
- 4 Levy G G, Motto D G, Ginsburg D. ADAMTS13 turns 3. Blood. 2005; 106 11-17
- 5 Haspel R L, Jarolim P. The “cutting” edge: von Willebrand factor-cleaving protease activity in thrombotic microangiopathies. Transfus Apher Sci. 2005; 32 177-184
- 6 George J N. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006; 354 1927-1935
- 7 Cal S, Obaya A J, Llamazares M, Garabaya C, Quesada V, Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002; 283 49-62
- 8 Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001; 276 41059-41063
- 9 Gerritsen H E, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001; 98 1654-1661
- 10 Plaimauer B, Zimmermann K, Volkel D et al.. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002; 100 3626-3632
- 11 Ruoslahti E, Pierschbacher M D. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986; 44 517-518
- 12 Dong J F. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005; 3 1710-1716
- 13 Soejima K, Mimura N, Hirashima M et al.. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J Biochem (Tokyo). 2001; 130 475-480
- 14 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001; 413 488-494
- 15 Turner N, Nolasco L, Tao Z, Dong J F, Moake J. Human endothelial cells synthesize and release ADAMTS-13. J Thromb Haemost. 2006; 4 1396-1404
- 16 Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 1999; 81 8-13
- 17 Liu L, Choi H, Bernardo A et al.. Platelet-derived VWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost. 2005; 3 2536-2544
- 18 Dong J F, Moake J L, Nolasco L et al.. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood. 2002; 100 4033-4039
- 19 Bernardo A, Ball C, Nolasco L, Moake J F, Dong J F. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood. 2004; 104 100-106
- 20 Chauhan A K, Motto D G, Lamb C B et al.. Systemic antithrombotic effects of ADAMTS13. J Exp Med. 2006; 203 767-776
- 21 Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol. 1996; 72 341-348
- 22 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood. 1997; 89 3097-3103
- 23 Dent J A, Galbusera M, Ruggeri Z M. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest. 1991; 88 774-782
- 24 Chung D W, Fujikawa K. Processing of von Willebrand factor by ADAMTS-13. Biochemistry. 2002; 41 11065-11070
- 25 Auton M, Cruz M A, Moake J. Conformational stability and domain unfolding of the von Willebrand factor A domains. J Mol Biol. 2007; 366 986-1000
- 26 Lam J K, Chion C K, Zanardelli S, Lane D A, Crawley J T. Further characterization of ADAMTS-13 inactivation by thrombin. J Thromb Haemost. 2007; 5 1010-1018
- 27 Crawley J T, Lam J K, Rance J B, Mollica L R, O'Donnell J S, Lane D A. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood. 2005; 105 1085-1093
- 28 Reiter R A, Knöbl P, Varadi K, Turecek P L. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood. 2002; 101 946-948
- 29 Studt J-D, Hovinga J AK, Antoine G et al.. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS-13 inhibitor: in vitro inhibition of ADAMTS-13 activity by hemoglobin. Blood. 2005; 105 542-544
- 30 Mannucci P M, Canciani M T, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood. 2001; 98 2730-2735
- 31 George J N, Li X, McMinn J R, Terrell D R, Vesely S K, Selby G B. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion. 2004; 44 294-304
- 32 Fuge R, Bird J M, Fraser A et al.. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol. 2001; 113 58-64
- 33 Singh N, Gayowski T, Marino I R. Hemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int. 1996; 9 68-75
- 34 Kojouri K, George J N. Thrombotic microangiopathy following allogeneic hematopoietic stem cell transplantation. Curr Opin Oncol. 2007; 19 148-154
- 35 Elliott M A, Nichols Jr W L, Plumhoff E A et al.. Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review. Mayo Clin Proc. 2003; 78 421-430
- 36 van der Plas R M, Schiphorst M E, Huizinga E G et al.. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood. 1999; 93 3798-3802
- 37 Arai S, Allan C, Streiff M, Hutchins G M, Vogelsang G B, Tsai H M. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J. 2001; 2 292-299
- 38 Peyvandi F, Siboni S M, Lambertenghi Deliliers D et al.. Prospective study on the behaviour of the metalloprotease ADAMTS13 and of von Willebrand factor after bone marrow transplantation. Br J Haematol. 2006; 134 187-195
- 39 Vesely S K, George J N, Lammle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003; 102 60-68
- 40 Mal H, Veyradier A, Brugiere O et al.. Thrombotic microangiopathy with acquired deficiency in ADAMTS 13 activity in lung transplant recipients. Transplantation. 2006; 81 1628-1632
- 41 Pham P T, Danovitch G M, Wilkinson A H et al.. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002; 74 1077-1080
- 42 Adachi T, Matsushita T, Ichihashi R et al.. High titer of ADAMTS13 inhibitor associated with thrombotic microangiopathy of the gut and skeletal muscle after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2006; 83 415-419
- 43 Park Y D, Yoshioka A, Kawa K et al.. Impaired activity of plasma von Willebrand factor-cleaving protease may predict the occurrence of hepatic veno-occlusive disease after stem cell transplantation. Bone Marrow Transplant. 2002; 29 789-794
- 44 Ko S, Okano E, Kanehiro H et al.. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl. 2006; 12 859-869
- 45 Ulinski T, Charpentier A, Colombat M et al.. From humoral rejection to generalized thrombotic microangiopathy-role of acquired ADAMTS13 deficiency in a renal allograft recipient. Am J Transplant. 2006; 6 3030-3036
- 46 Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res. 1999; 59 2244-2250
- 47 Mannucci P M, Karimi M, Mosalaei A, Canciani M T, Peyvandi F. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica. 2003; 88 454-458
- 48 Koo B H, Oh D, Chung S Y et al.. Deficiency of von Willebrand factor-cleaving protease activity in the plasma of malignant patients. Thromb Res. 2002; 105 471-476
- 49 Blot E, Decaudin D, Veyradier A, Bardier A, Zagame O L, Pouillart P. Cancer-related thrombotic microangiopathy secondary to von Willebrand factor-cleaving protease deficiency. Thromb Res. 2002; 106 127-130
- 50 Fontana S, Gerritsen H E, Kremer Hovinga J, Furlan M, Lammle B. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. Br J Haematol. 2001; 113 100-102
- 51 Forman R B, Benkel S A, Novik Y, Tsai H M. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. Acta Haematol. 2003; 109 150-152
- 52 Böhm M, Gerlach R, Beecken W D, Scheuer T, Stier-Bruck I, Scharrer I. ADAMTS-13 activity in patients with brain and prostate tumors is mildly reduced, but not correlated to stage of malignancy and metastasis. Thromb Res. 2003; 111 33-37
- 53 Hymes K B, Karpatkin S. Human immunodeficiency virus infection and thrombotic microangiopathy. Semin Hematol. 1997; 34 117-125
- 54 Gunther K, Garizio D, Dhlamini B. The pathogenesis of HIV-related thrombotic thrombocytopenic purpura - is it different?. ISBT Science Series. 2006; 1 246-250
- 55 Miller R F, Scully M, Cohen H et al.. Thrombotic thrombocytopenic purpura in HIV infected patients. Int J STD AIDS. 2005; 16 538-542
- 56 Sahud M A, Claster S, Liu L, Ero M, Harris K, von Furlan M. Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002; 116 909-911
- 57 Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion. 2007; 47 1710-1716
- 58 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases. Blood. 2001; 98 1765-1772
- 59 Tsai H M, Chandler W L, Sarode R et al.. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001; 49 653-659
- 60 Amirlak I, Amirlak B. Hemolytic uremic syndrome: an overview. Nephrologie. 2006; 11 213-218
- 61 Veyradier A, Obert B, Haddad E et al.. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr. 2003; 142 310-317
- 62 George J N, Vesely S K, James J A. Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007; 100 512-514
- 63 Gungor R, Furlan M, Lammle B, Kuhn F, Seger R A. Acquired deficiency of von Willebrand factor-cleaving protease in a patient suffering from acute systemic lupus erythematosus. Rheumatology. 2001; 40 940-942
- 64 Matsuda J, Sanaka T, Gohchi K et al.. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand factor-cleaving protease. Lupus. 2002; 11 463-464
- 65 Mannucci P M, Vanoli M, Forza I, Canciani M T, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). Haematologica. 2003; 88 914-918
- 66 Peyvandi F, Ferrari S, Lavoretano S, Canciani M T, Mannucci P M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2004; 127 433-439
- 67 Rick M E, Austin H, Leitman S F, Krizek D M, Aronson D L. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. Am J Hematol. 2004; 75 96-100
- 68 Starck M, Abedinpour F, Dendorfer U et al.. Acquired thrombotic thrombocytopenic purpura as the presenting symptom of systemic lupus erythematosus. Successful treatment with plasma exchange and immunosuppression-report of two cases. Eur J Haematol. 2005; 75 436-440
- 69 Enami T, Suzuki T, Ito S et al.. Successful treatment of refractory thrombotic thrombocytopenic purpura with cyclosporine and corticosteroids in a patient with systemic lupus erythematosus and antibodies to ADAMTS13. Intern Med. 2007; 46 1033-1037
- 70 Rieger M, Mannucci P M, Kremer Hovinga J A et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106 1262-1267
- 71 Kobayashi T, Wada H, Kamikura Y et al.. Decreased ADAMTS13 activity in plasma from patients with thrombotic thrombocytopenic purpura. Thromb Res. 2007; 119 447-452
- 72 Amoura Z, Costedoat-Chalumeau N, Veyradier A et al.. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004; 50 3260-3264
- 73 Hirata S, Okamoto H, Ohta S et al.. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease. Rheumatology. 2006; 45 1046-1047
- 74 Sato T, Hanaoka R, Ohshima M et al.. Analyses of ADAMTS13 activity and its inhibitor in patients with thrombotic thrombocytopenic purpura secondary to connective tissue diseases: observations in a single hospital. Clin Exp Rheumatol. 2006; 24 454-455
- 75 Liu F, Feys H B, Dong N, Zhao Y, Ruan C. Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus. Thromb Haemost. 2006; 95 749-750
- 76 Coppo P, Bengoufa D, Veyradier A et al.. Reseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83 233-244
- 77 Zakarija A, Bennet C. Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005; 31 681-690
- 78 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004; 103 4043-4049
- 79 Nakazawa Y, Hashikura Y, Urata K et al.. Von Willebrand factor-cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report. Liver Transpl. 2003; 9 1328-1333
- 80 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000; 342 1773-1777
- 81 Zakarija A, Bandarenko N, Pandey D K et al.. Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004; 35 533-537
- 82 Tsai H M, Rice L, Sarode R, Chow T W, Moake J L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000; 132 794-799
- 83 Bennett C L, Weinberg P D, Rozenberg-Ben-Dror K, Yarnold P R, Kwaan H C, Green D. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998; 128 541-544
- 84 Sugio Y, Okamura T, Shimoda K et al.. Ticlopidine-associated thrombotic thrombocytopenic purpura with an IgG-type inhibitor to von Willebrand factor-cleaving protease activity. Int J Hematol. 2001; 74 347-351
- 85 Bennett C L, Kim B, Zakarija A SERF-TTP Research Group et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007; 50 1138-1143
- 86 Lesesne J B, Rothschild N, Erickson B et al.. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989; 7 781-789
- 87 Cantrell J E, Phillips T M, Schein P S. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985; 3 723-734
- 88 Nagaya S, Wada H, Oka K et al.. Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C. Am J Hematol. 1995; 50 237-243
- 89 Fung M C, Storniolo A M, Nguyen B, Arning M, Brookfield W, Vigil J. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999; 85 2023-2032
- 90 Humphreys B D, Sharman J P, Henderson J M et al.. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004; 100 2664-2670
- 91 Ravandi-Kashani F, Cortes J, Talpaz M, Kantarjian H M. Thrombotic microangiopathy associated with interferon therapy for patients with chronic myelogenous leukemia: coincidence or true side effect?. Cancer. 1999; 85 2583-2588
- 92 Al-Zahrani H, Gupta V, Minden M D, Messner H A, Lipton J H. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44 471-475
- 93 Kojouri K, Vesely S K, George J N. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med. 2001; 135 1047-1051
- 94 Baliga R S, Wingo C S. Quinine induced HUS-TTP: an unusual presentation. Am J Med Sci. 2003; 326 378-380
- 95 Gottschall J L, Elliot W, Lianos E, McFarland J G, Wolfmeyer K, Aster R H. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood. 1991; 77 306-310
- 96 Gottschall J L, Neahring B, McFarland J G, Wu G G, Weitekamp L A, Aster R H. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol. 1994; 47 283-289
- 97 Mauro M, Zlatopolskiy A, Raife T J, Laurence J. Thienopyridine-linked thrombotic microangiopathy: association with endothelial cell apoptosis and activation of MAP kinase signalling cascades. Br J Haematol. 2004; 124 200-210
- 98 Medina P J, Sipols J M, George J N. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001; 8 286-293
- 99 George J N. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2003; 10 339-344
- 100 Hulstein J J, van Runnard Heimel P J, Franx A et al.. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost. 2006; 4 2569-2575
- 101 Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci P M. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica. 2003; 88 1029-1034
- 102 Lämmle B, Kremer Hovinga J A, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost. 2005; 3 1663-1675
- 103 Loof A H, van Vliet H H, Kappers-Klunne M C. Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. Br J Haematol. 2001; 112 1087-1088
- 104 Bianchi V, Robles R, Alberio L, Furlan M, Lammle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002; 100 710-713
- 105 Moore J C, Hayward C P, Warkentin T E, Kelton J G. Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood. 2001; 98 1842-1846
- 106 Sosothikul D, Seksarn P, Pongsewalak S, Thisyakorn U, Lusher J. Activation of endothelial cells, coagulation and fibrinolysis in children with Dengue virus infection. Thromb Haemost. 2007; 97 627-634
- 107 Matsuyama T, Uemura M, Ishikawa M et al.. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res. 2007; 31(Suppl 1) S27-35
- 108 Feys H B, Canciani M T, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci P M. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol. 2007; 138 534-540
- 109 Mannucci P M, Capoferri C, Canciani M T. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol. 2004; 126 213-218
- 110 Ono T, Mimuro J, Madoiwa S et al.. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood. 2006; 107 528-534
- 111 Nguyen T C, Liu A, Liu L et al.. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica. 2007; 92 121-124
- 112 Kremer Hovinga J A, Zeerleder S, Kessler P et al.. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007; , In press
- 113 Martin K, Borgel D, Lerolle N et al.. Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med. 2007; 35 2375-2382
- 114 He S, Cao H, Magnusson C G et al.. Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein. Thromb Res. 2001; 103 241-248
- 115 Yoo G, Blomback M, Schenck-Gustafsson K, He S. Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation. Br J Haematol. 2003; 121 123-129
- 116 Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost. 2006; 4 2490-2493
- 117 Chion C K, Doggen C J, Crawley J T, Lane D A, Rosendaal F R. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood. 2007; 109 1998-2000
- 118 Matsukawa M, Kaikita K, Soejima K et al.. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am J Cardiol. 2007; 100 758-763
- 119 Ruan C, Dai L, Su J, Wang Z, Ruan C. The frequency of P475S polymorphism in von Willebrand factor-cleaving protease in the Chinese population and its relevance to arterial thrombotic disorders. Thromb Haemost. 2004; 91 1257-1258
- 120 Bongers T N, de Maat M P, van Goor M L et al.. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke. 2006; 37 2672-2677
- 121 Mannucci P M, Parolari A, Canciani M T, Alemanni F, Camera M. Opposite changes of ADAMTS-13 and von Willebrand factor after cardiac surgery. J Thromb Haemost. 2005; 3 397-399
- 122 Lo B, Nierich A P, Kalkman C J, Fijnheer R. Relatively increased von Willebrand factor activity after off-pump coronary artery bypass graft surgery. Thromb Haemost. 2007; 97 21-26
- 123 Lian E C. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond. Semin Thromb Hemost. 2005; 31 625-632
Massimo FranchiniM.D.
Servizio di Immunoematologia e Trasfusione - Centro Emofilia, Azienda Ospedaliera
di Verona, P.le Stefani 1
37126 - Verona, Italy
Email: massimo.franchini@univr.it